Comparing two surgical approaches for early-stage lung cancer with ground-glass nodules

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of mediastinal lymph node dissection versus spared mediastinal lymph node dissection in patients with stage I non-small cell lung cancer (NSCLC) characterized by ground-glass nodules. It is a prospective, multicenter, randomized trial involving 1,362 patients, with an enrollment period of three years followed by a five-year observation period. The study aims to compare overall survival and disease-free survival rates between the two surgical approaches, focusing on the unique characteristics of ground-glass nodules that may influence treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Thin-slice HRCT shows single GGN with C/T ≤ 0.5 and no lymph node metastasis;
* Clinical stage IA NSCLC (TNM 8th classification) diagnosed prior or in surgery;
* No history of malignancies within past 5 years or lung surgery;
* No anti-cancer treatment prior to surgery.

Exclusion Criteria:

* Simultaneous or metachronous (within the past 5 years) double cancers;
* Active bacterial or fungous infection;
* Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema;
* Systemic steroidal medication;
* Uncontrollable diabetes mellitus; (vi) Uncontrollable hypertension or history of severe heart disease, heart failure.

Where it's running

• Ethics review board of Tianjin Medical University Cancer Institute and Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Principal investigator: Zhenfa Zhenfa, MD — Tianjin Medical University Cancer Institute and Hospital
• Study coordinator: Zhenfa Zhang, MD
• Email: zhangzhenfa1973@163.com
• Phone: +862223340123

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-assisted longitudinal CT to guide indeterminate lung nodules

  This trial tests whether giving doctors an AI report that tracks nodules over serial CT scans helps reduce unnecessary benign lung resections in patients with indeterminate nodules.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07895277

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• Telerehabilitation exercise program after lung cancer surgery

  A remote rehabilitation program with guided exercises is tested to help adults after lung cancer surgery recover better.

  Recruiting University of Seville · Seville, Andalusia · NCT07861282

• Impact of Exercise on Tumor Immunity in NSCLC Patients Receiving Neoadjuvant Chemo-Immunotherapy

  A structured exercise program is being tested to see if it boosts immune cells in the tumor for patients with resectable NSCLC undergoing pre-surgery chemo-immunotherapy.

  Recruiting at 2 sites Centre Leon Berard · Lyon, Rhône and 1 other locations · NCT07786909

• Low-Dose CT Lung Cancer Screening in Kuwait: Feasibility and Uptake

  This pilot tests whether offering low-dose CT lung cancer screening to high-risk adults in Kuwait is workable and acceptable, with about 500 participants completing a baseline scan.

  Recruiting Chest Diseases Hospital, Ministry of Health, Kuwait · Kuwait City · NCT07766538

• Nitride-based Raman biochip for lung cancer diagnosis and monitoring

  A large observational study in Taiwan will test whether a blood-based nitride-based Raman biochip can help diagnose lung cancer and monitor patients over time.

  Recruiting Taichung Veterans General Hospital · Taichung · NCT07755020

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.